Manidipine Viatris

Manidipine, the active ingredient in Manidipine Viatris, is a calcium channel blocker presented as an oral dosage form for oral use. It is used to treat hypertension in adult patients.

GNH USA supplies Manidipine Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manidipine is a dihydropyridine calcium‑channel blocker indicated for the management of high blood pressure.

- Essential hypertension: reduces systolic and diastolic pressure by relaxing peripheral arteries. - Isolated systolic hypertension: lowers elevated systolic readings while maintaining diastolic stability. - Renal hypertension: improves renal perfusion pressure by decreasing systemic vascular resistance.

Manidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: warm sensation, usually resolves with continued therapy. - Peripheral edema: swelling of ankles or lower legs. - Dizziness or light‑headedness, especially after standing. - Nausea or abdominal discomfort. - Tachycardia: increased heart rate without other cardiac symptoms.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Angioedema: swelling of face, lips, tongue, or throat. - Myocardial infarction: chest pain or discomfort suggestive of heart attack. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Allergic reactions: rash, pruritus, or anaphylaxis. - Arrhythmias: irregular heart rhythms requiring monitoring.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential risks.

- Blood pressure monitoring: check baseline and periodic readings to avoid excessive hypotension. - Hepatic impairment: use with caution; dose adjustment may be required. - Concomitant antihypertensives: assess for additive blood‑pressure‑lowering effects. - Cardiovascular disease: monitor for signs of ischemia or heart failure. - Sudden discontinuation: taper gradually to prevent rebound hypertension. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Manidipine can interact with several drug classes, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations. - Other calcium‑channel blockers: additive vasodilatory effect leading to severe hypotension. - Potent antihypertensives (e.g., ACE inhibitors, ARBs): risk of excessive blood‑pressure reduction.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic levels. - NSAIDs: can blunt antihypertensive response. - Diuretics: may enhance orthostatic hypotension. - Beta‑blockers: monitor heart rate and blood pressure. - Grapefruit juice: may modestly increase drug exposure.